Patent · US Active

MDR E. coli immunogen

US12274742B2 · kind B2 · utility

0Cited by

18References

11Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Eszter Nagy · Wien, AT
Gabor Nagy · Redmond, US
Valeria SZIJARTO · Wien, AT
Zoltán Magyarics · Wien, AT
Irina MIRKINA · Wien, AT
Luis Gauchalla · Wien, AT
Adriana BADARAU · Wien, AT
Gerhild Zauner · Wien, AT
Jolanta Lukasiewicz · Wrocław, PL

Key dates

Filing date	Nov 22, 2022
Grant date	Apr 15, 2025
Priority date	—
Expiry date	Nov 22, 2042

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.